Fused tricyclic heterocyclic compounds as HIV integrase inhibitors

US9643982B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Paul J. Coleman · Wallingford, US
• Timothy J. Hartingh · Richlandtown, US
• Izzat T. Raheem · Doylestown, US
• John D. Schreier · Philadelphia, US
• John T. Sisko · Lansdale, US
• John S. Wai · Harleysville, US
• Thomas H. Graham · Somerville, US
• Lihong Hu · Shanghai, CN
• Xuanjia Peng · Shanghai, CN

Key dates

• Filing date: Apr 18, 2014
• Grant date: May 9, 2017
• Expiry date: Apr 18, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8, A, X and n are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.